COVID-19-associated fungal infections

Nature Microbiology, Journal Year: 2022, Volume and Issue: 7(8), P. 1127 - 1140

Published: Aug. 2, 2022

Language: Английский

---

Candida auris Genetics and Emergence

Annual Review of Microbiology, Journal Year: 2023, Volume and Issue: 77(1), P. 583 - 602

Published: July 5, 2023

Candida auris is a multidrug-resistant fungal pathogen that presents serious threat to global human health. Since the first reported case in 2009 Japan, C. infections have been more than 40 countries, with mortality rates between 30% and 60%. In addition, has potential cause outbreaks health care settings, especially nursing homes for elderly patients, owing its efficient transmission via skin-to-skin contact. Most importantly, show pronounced sometimes untreatable clinical drug resistance all known antifungal classes, including azoles, amphotericin B, echinocandins. this review, we explore causes of rapid spread auris. We also highlight genome organization mechanisms propose future research directions should be undertaken curb pathogen.

Language: Английский

---

Candidiasis and Other Emerging Yeasts

Current Fungal Infection Reports, Journal Year: 2023, Volume and Issue: 17(1), P. 15 - 24

Published: Jan. 31, 2023

Language: Английский

---

Global prevalence and subgroup analyses of coronavirus disease (COVID‐19) associated Candida auris infections (CACa): A systematic review and meta‐analysis

Mycoses, Journal Year: 2022, Volume and Issue: 65(7), P. 683 - 703

Published: May 12, 2022

Increased hospitalisation rates in the Coronavirus disease 19 (COVID-19) era lead to a new wave of hospital-acquired infections such as emerging multidrug-resistant Candida auris. We aimed evaluate and estimate global prevalence coronavirus-associated C. auris infection (CACa). searched related databases between December 2019 April 2022 for studies that reported data about CACa. Meta-analysis was performed using MedCalc software version 20.104 according DerSimonian Laird method applying random-effects model. evaluated heterogeneity χ2 -based Q statistic (significant p-value < .1) I2 (>75% indicative 'notable' heterogeneity). Moreover, if possible, an odds ratio (OR) analysis eligible data. Our meta-analysis includes ten studies, including 1942 patients hospitalised with COVID-19; 129 were cases. The overall pooled CACa estimated at 5.7%. mortality rate 67.849%. Hypertension most prevalent comorbidity (59.374%), followed by diabetes mellitus (52.898%) cardiovascular diseases (31.392%). Men 80.012% 3.27 times more prone getting infected concluded decreased during COVID-19 pandemic gradient changed from Asia America. Unfortunately, there are many descriptive duplicate content field epidemiology which increasing every day. suggest further non-descriptive accurately establish cause-and-effect relationships infections.

Language: Английский

---

Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era

Antibiotics, Journal Year: 2022, Volume and Issue: 11(6), P. 771 - 771

Published: June 4, 2022

The objectives of this study were to investigate the incidence candidemia, as well factors associated with Candida species distribution and fluconazole resistance, among patients admitted intensive care unit (ICU) during COVID-19 pandemic, compared two pre-pandemic periods. All ICU due from March 2020 October 2021, periods (2005-2008 2012-2015), who developed included. During period, candidemia was 10.2%, significantly higher 3.2% 4.2% in periods, respectively. proportion non-albicans increased (from 60.6% 62.3% 75.8%, respectively), a predominance C. parapsilosis. A marked increase resistance 31% 37.7% 48.4%, respectively) also observed. Regarding total patient population (n = 205), independently length stay (LOS) before (OR 1.03; CI: 1.01-1.06, p 0.003), whereas presence shock at onset albicans 6.89; 2.2-25, 0.001), fluconazole-susceptible 0.23; 0.07-0.64, 0.006). In conclusion, substantial increases non-albicansCandida species, found COVID-19, At onset, prolonged LOS fluconazole-resistant species.

Language: Английский

---

Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID‐19) patients: A systematic review

Mycoses, Journal Year: 2022, Volume and Issue: 65(6), P. 613 - 624

Published: April 20, 2022

Candida auris is an emerging multidrug-resistant pathogen in intensive care settings (ICU). During the coronavirus disease 19 (COVID-19) pandemic, ICU admissions were overwhelmed, possibly contributing to C. outbreak COVID-19 patients.The present systematic review addresses prevalence, underlying diseases, iatrogenic risk factors, treatment and outcome of infections patients.MEDLINE, Scopus, Embase, Web Science LitCovid databases systematically searched with appropriate keywords from 1 January 2020 31 December 2021.A total 97 cases identified patients. The pooled prevalence (encompassing candidemia non-candidemia cases) patients was 14%. major diseases diabetes mellitus (42.7%), hypertension (32.9%) obesity (14.6%), followed by factors such as a central venous catheter (76.8%%), unit (ICU) stay (75.6%) broad-spectrum antibiotic usage (74.3%). There no significant differences among non-candidemia/colonisation cases. mortality rate cohort 44.4%, whereas, patients, 64.7%.This study shows that remains unchanged pandemic. Hospital-acquired may contribute clinical illness. Proper infection control practices hospital surveillance stop future outbreaks during

Language: Английский

---

Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission

Journal of Fungi, Journal Year: 2022, Volume and Issue: 8(3), P. 305 - 305

Published: March 16, 2022

There is scarce information on the actual incidence of candidemia in COVID-19 patients. In addition, comparative studies episodes and non-COVID-19 patients are heterogeneous. Here, we assessed real incidence, epidemiology, etiology patients, compared them with those without (2020 vs. 2019 2020, respectively). We also genotyped all C. albicans, parapsilosis, tropicalis isolates (n = 88), causing both groups, providing for first time a genotypic characterization gathered either or non-COVID-19. Incidence was higher than (4.73 0.85 per 1000 admissions; 3.22 1.14 10,000 days stay). No substantial intergroup differences were found, including mortality. Genotyping proved presence low number involved clusters, allowing us to rule out rampant patient-to-patient Candida transmission. The four two had catheter-related diagnosed wave, which demonstrates breaches catheter management policies occurring such an overwhelming situation. conclusion, significantly COVID-19. However, genotyping shows that this increase not due uncontrolled intrahospital

Language: Английский

---

Social determinants of health as drivers of fungal disease

EClinicalMedicine, Journal Year: 2023, Volume and Issue: 66, P. 102325 - 102325

Published: Nov. 18, 2023

Disparities in social determinants of health (SDOH) play a significant role causing inequities globally. The physical environment, including housing and workplace can increase the prevalence spread fungal infections. A number professions are associated with increased infection risk low pay, which may be linked to crowded sub-optimal living conditions, exposure organisms, lack access quality care, for infection. Those involved displaced from areas armed conflict have an invasive Lastly, plant pathogens already threaten food security, will become more problematic global climate change. Taken together, disparities SDOH contracting More emphasis needs placed on systematic approaches better understand impact reducing these disparities.

Language: Английский

---

Candida auris Infections

New England Journal of Medicine, Journal Year: 2024, Volume and Issue: 391(20), P. 1924 - 1935

Published: Nov. 20, 2024

C. auris, a serious public health threat that may have emerged because of climate change, persists on human skin and inanimate objects, frequently causing difficult-to-control outbreaks in care facilities.

Language: Английский

---

COVID-19-associated candidiasis and the emerging concern of Candida auris infections

Journal of Microbiology Immunology and Infection, Journal Year: 2022, Volume and Issue: 56(4), P. 672 - 679

Published: Dec. 14, 2022

The incidence of COVID-19-associated candidiasis (CAC) is increasing, resulting in a grave outcome among hospitalized patients with COVID-19. most alarming condition the increasing multi-drug resistant Candida auris infections COVID-19 worldwide. therapeutic strategy towards CAC caused by common species, such as albicans, tropicalis, and glabrata, similar to pre-pandemic era. For non-critically ill or those low risk azole resistance, fluconazole remains drug choice for candidemia. critically patients, history recent exposure high echinocandins are recommended first-line therapy. Several novel agents alone combination traditional antifungal potential options future. However, multidrug-resistant C. infection, only effective. Infection prevention control policies, including strict isolation carrying regular screening non-affected suggested prevent spread Whole-genome sequencing may be used understand epidemiology healthcare-associated better these infections.

Language: Английский

---